Hutchison China Meditech Limited Vesting of awards under Long Term Incentive Plan (2986F)
09 Mars 2020 - 8:00AM
UK Regulatory
TIDMHCM
RNS Number : 2986F
Hutchison China Meditech Limited
09 March 2020
Vesting of awards under the Long Term Incentive Plan
London: Monday, March 9, 2020: Hutchison China MediTech Limited
("Chi-Med") (Nasdaq/AIM: HCM) announces that following the
announcement of the 2019 annual results of Chi-Med on March 3,
2020, the following awards granted under the Long Term Incentive
Plan ("LTIP") on March 15, 2017 to Mr Christian Hogg, Mr Johnny
Cheng and Dr Weiguo Su were vested on March 6, 2020:-
Award Holders Number of American depositary
shares ("ADS")
Person Discharging Managerial Responsibilities
Mr Christian Hogg (Executive Director and
Chief Executive Officer) 14,975
Mr Johnny Cheng (Executive Director and
Chief Financial Officer) 5,857
Dr Weiguo Su (Executive Director and Chief
Scientific Officer) 10,475
Total 31,307
==============================
The notifications set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation.
(a) Mr Christian Hogg
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Christian Hogg
------------------------------------------------------- ------------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Executive Officer
------------------------------------------------------- ------------------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------------------- ------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
------------------------------------------------------- ------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
------------------------------------------------------- ------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---------------------------------------------------------------------------------------------------------------
Description of the financial instrument, type of ADS each representing five Ordinary Shares of
a) instrument US$0.10
Identification code ADS ISIN: US44842L1035
------------------------------------------------------- ------------------------------------------------------
b) Nature of the transaction Vesting of awards granted on March 15, 2017 under
Chi-Med's LTIP
------------------------------------------------------- ------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 14,975 ADS
-----------
------------------------------------------------------- ------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------------------------------- ------------------------------------------------------
e) Date of the transaction 2020-03-06
------------------------------------------------------- ------------------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------------------------- ------------------------------------------------------
(b) Mr Johnny Cheng
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Johnny Cheng
------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Financial Officer
------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
------------------------------------------------------- -------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing five Ordinary Shares of US$0.10
instrument ADS ISIN: US44842L1035
Identification code
------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Vesting of awards granted on March 15, 2017 under
Chi-Med's LTIP
------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 5,857 ADS
----------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- -------------------------
e) Date of the transaction 2020-03-06
-------------------------- -------------------------
f) Place of the transaction Outside a trading venue
-------------------------- -------------------------
(c) Dr Weiguo Su
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Weiguo Su
------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Scientific Officer
------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
------------------------------------------------------- -------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing five Ordinary Shares of US$0.10
instrument ADS ISIN: US44842L1035
Identification code
------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Vesting of awards granted on March 15, 2017 under
Chi-Med's LTIP
------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 10,475 ADS
-----------
------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 2020-03-06
-------------------------- -------------------------
f) Place of the transaction Outside a trading venue
-------------------------- -------------------------
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical
company committed, over the past twenty years, to the discovery and
global development of targeted therapies and immunotherapies for
the treatment of cancer and immunological diseases. It has a
portfolio of eight cancer drug candidates currently in clinical
studies around the world and extensive commercial infrastructure in
its home market of China. For more information, please visit:
www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Asia - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
jlo@brunswickgroup.com
- Zhou Yi, Brunswick +852 97 83 6894 (Mobile)
y zhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUPUBAWUPUGUQ
(END) Dow Jones Newswires
March 09, 2020 03:00 ET (07:00 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
